Company / Operating Income
West Pharmaceutical Services Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$584.9M
FY2025
5-year range
$296.6M / $676.0M
FY2021-FY2025
Trend
+2.6%
vs FY2024
Sector context
#38 of 156
Health Care
What the data says
West Pharmaceutical Services's operating income of $585M is higher than 76% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 10 years, ranging from $182M in FY2016 to $676M in FY2023.
Based on SEC 10-K filings.
$585M in FY2025 with a 5-year CAGR of +19.5%. Top quartile in the Health Care sector.
Declined from $676M to $585M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +12.9%
- 5-Year CAGR
- +19.5%
- 10-Year CAGR
- -
Sector benchmark
-20.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.5%, indicating consistent growth.
- In FY2025, operating income increased 2.6% year-over-year.
- Ranks #38 out of 156 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $584.9M | +2.6% |
| FY2024 | $569.9M | -15.7% |
| FY2023 | $676.0M | +66.1% |
| FY2022 | $406.9M | +37.2% |
| FY2021 | $296.6M | +23.4% |
| FY2020 | $240.3M | -19.0% |
| FY2019 | $296.6M | +23.4% |
| FY2018 | $240.3M | +6.4% |
| FY2017 | $225.8M | +24.1% |
| FY2016 | $182.0M | +12.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026